IGHE and asthma: We performed an in‐depth appraisal of indirect head‐to‐head comparisons of biologics approved for asthma, including anti‐IL5/5Rα (mepolizumab, benralizumab), anti‐IL4Rα (dupilumab), anti‐TSLP (tezepelumab) and anti‐IgE (omalizumab), which was neither a systematic review nor a meta‐analysis.